ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2304건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2276 | Completed | A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection | Coronavirus | Drug: Fluvoxamine Drug: Placebo |
Phase 2 | Washington University School of Medicine | OTHER | 152 | All | 18 Years | BJC, Belleville, Illinois, United States Washington University School of Medicine, Saint Louis, Missouri, United States |
| 2275 | Completed | A First-In-Human Phase 1b Study of AmnioPul-02 in COVID-19 / Other LRTI | COVID-19 | Drug: AmnioPul-02 | Phase 1 | Amniotics AB | INDUSTRY | 6 | All | 18 Years ~ 80 Years | Infection clinic, Malmo, Skane, Sweden |
| 2274 | Recruiting | A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 | SARS-CoV-2 | Biological: LVRNA009 Other: 0.9%NaCl |
Phase 3 | AIM Vaccine Co., Ltd., AIM Innovation Biotechnology (Shanghai) Co., Ltd, Ningbo Rongan Biological Pharmaceutical Co., Ltd., LiveRNA Therapeutics Inc. | INDUSTRY | 34000 | All | 18 Years | KEMRI CRDR Research Annex, Siaya Country Referral Hospital, Siaya, Kenya |
| 2273 | Active, not recruiting | A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells) | COVID-19 | Biological: Recombinant COVID-19 vaccine (Sf9 cells) Other: Placebo control |
Phase 3 | WestVac Biopharma Co., Ltd., West China Hospital | INDUSTRY | 40000 | All | 18 Years | Puskesmas Ciketingudik, Bekasi, Jiangsu, Indonesia Permata Hospital, Bekasi, Indonesia Brawijaya University Hospital, Malang, Indonesia Universitas Muhammadiyah Malang Hospital, Malang, Indonesia Airlangga University Hospital, Surabaya, Indonesia Husada Utama Hospital, Surabaya, Indonesia Moi Teaching and Referral Hospital，Eldoret (MTRH), Eldoret, Kenya KAVI-Institute of Clinical Research, University of Nairobi, Nairobi, Kenya Hospital General Dr. Manuel Gea Gonzalez, Ciudad de Mexico, Mexico Invesclinic MX, Ciudad de Mexico, Mexico Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango, Mexico Centro de Investigacion Clinica y medicina traslacional (CIMeT), Guadalajara, Mexico Clinica de Enfermedades Cronicas y de Procedimientos Especiales, Morelia, Mexico SMIQ，S de R.L. de C.V., Queretaro, Mexico FS Scientia Pharma SA de CV, San Luis Potosi, Mexico Bharatpur Hospital, Kathmandu, Nepal Perpetual Succour Hospital - The Research Institute, Cebu City, Philippines De La Salle Medical and Health Sciences Institute, Dasmarinas, Philippines The Medical City - Iloilo, Iloilo City, Philippines West Visayas State University Medical Center, Iloilo City, Philippines Tropical Disease Foundation, Makati City, Philippines Makati Medical Center, Makati City, Philippines Quirino Memorial Medical Center, Quezon City, Philippines St Luke Medical Centre - BGC, Taguig, Philippines |
| 2272 | Unknown status | A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19 | COVID-19 Vaccine | Biological: MVC-COV1901(3 Months) Biological: MVC-COV1901(6 Months) |
Phase 4 | Taoyuan General Hospital, Medigen Vaccine Biologics Corp. | OTHER_GOV | 200 | All | 20 Years ~ 64 Years | Taoyuan General Hospital, Taoyuan, Taiwan |
| 2271 | Completed | A Heterologous Prime-boost Study to Evaluate Immunogenicity and Safety of mRNA-1273 With MVC-COV1901 in Adults | Covid19 Vaccine | Biological: Homologous boost schedule Biological: Heterologous boost schedule |
Phase 4 | National Taiwan University Hospital | OTHER | 220 | All | 20 Years ~ 69 Years | National Taiwan University Hospital, Taipei, Taiwan |
| 2270 | Active, not recruiting | A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated | Covid19 | Biological: 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated Biological: 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated Biological: 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated Biological: 2 doses of vaccine |
Phase 4 | China National Biotec Group Company Limited, Beijing Institute of Biological Products Co Ltd. | INDUSTRY | 4400 | All | 3 Years | Yanjin County Center for Disease Control and Prevention, Xinxiang, Henan, China |
